Investor Relations

HOME>Investor Relations

IR Calendar

2019

October 30: Announcement of FY2019 2nd Quater Financial Results

July 29: Announcement of FY2019 1st Quater Financial Results

June 21: The 12th Ordinary General Meeting of Shareholders

IR Calendar list

What's New

2019

October 11		Corporate Governance Corporate Governance Report
October 9		Mitsubishi Tanabe Pharma enters into a licensing agreement with Viela Bio for inebilizumab, a treatment agent for neuromyelitis optica spectrum disorder, in Japan and other Asian regions
October 2		Opinion Sharing Meeting on ESG [Transcript]
October 2		Notification of acceptance of the New Drug Submission for Scientific Review of VLP Seasonal Influenza Vaccines（MT-2271）by Health Canada
October 1		CSR Information updated
September 30		Opinion Sharing Meeting on ESG [Video]
September 30		Mitsubishi Tanabe Pharma to participate in new screening program through the Global Health Innovative Technology Fund ～Targeting treatments for infectious diseases that burden the developing countries～
September 27		Opinion Sharing Meeting on ESG [Material]
September 24		NMPA accepts our filing for TENELIA, a treatment agent for type 2 diabetes mellitus in China
September 20		Notice Regarding the Conclusion of Joint Sales Promotion Contract Concerning Alesion Ophthalmic Solution 0.05% and Alesion LX Ophthalmic Solution 0.1% between Mitsubishi Tanabe Pharma and Santen Pharmaceutical Co., Ltd.
September 18		Mitsubishi Tanabe Pharma Included in the Dow Jones Sustainability Asia Pacific Index
September 17		Mitsubishi Tanabe Pharma and Daiichi Sankyo announce alliance for ALS treatment agent edaravone in Brazil
September 4		Notice regarding the launch of Collategene intramuscular injection 4 mg, an HGF gene therapy product
August 30		Monitoring indicators on “Materiality”
August 28		The Start of a Phase 3 Clinical Trial of Continuous Subcutaneous Liquid levodopa/carbidopa Administration (ND0612) for patients with fluctuating Parkinson’s disease
August 8		PhaseⅠClinical Trial study protocol for MT-3921 in Patients with Spinal Cord Injury submitted to the US IND
August 8		Regulatory Approval for Marketing Cariprazine (MP-214) for the Treatment of Schizophrenia in Part of the ASEAN (Singapore and Thailand)
August 7		NMPA approved Japan-originated ALS treatment Edaravone in China
August 6		Commencement of R&D of Gene Therapy Product for Hemophilia B
July 31		IR Meeting for FY2019 1st Quarter Business Results[Transcript]
July 29		IR Meeting for FY2019 1st Quarter Business Results[Material][Audio]
July 29		Announcement of FY2019 1st Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
July 23		Submission of Vadadustat (MT-6548) New Drug Application in Japan for renal anemia
June 24		Corporate Governance Report
June 21		Notice of Resolution of the 12th Ordinary General Meeting of Shareholders ⇒Results of the Exercise of Voting Rights(June 24, 2019)
May 30		Withdrawal of Marketing Authorization Application of edaravone for ALS in the European Union
May 29		Launch of SIMPONI Subcutaneous Injection 50mg Autoinjector
May 24		Notice of Convocation of the 12th Ordinary General Meeting of Shareholders
May 16		IR Meeting for FY2018 Business Results[Transcript]
May 13		IR Meeting for FY2018 Business Results[Material][Video]
May 10		Announcement of Financial Results for FY2018 ⇒R&D Pipeline "State of New Product Development"
May 7		Analysts meeting on Revision to Consolidated Financial Forecasts for FY2018[Transcript]
April 26		Mitsubishi Tanabe Pharma and Salix enter into a licensing agreement for MT-1303, a therapeutic agent for autoimmune diseases
April 26		Medicago announced that its proprietary plant-based production platform, Proficia was awarded "Best New Vaccine Technology/Platform" at the World Vaccine Congress in Washington, D.C.
April 24		Analysts meeting on Revision to Consolidated Financial Forecasts for FY2018 [Material][Audio]
April 24		Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019
April 15		For the ALS patients in the world, we hope to deliver Japan-originated ALS treatment―NMPA accepts our filing for Radicut to treat ALS in China
April 11		Notice Regarding Reorganization of Research, Production, and Technology Bases
March 28		The Global Health Innovative Technology Fund provides grant for joint research into anti-malarial drugs conducted by Mitsubishi Tanabe Pharma and a malaria research institution
March 20		Aiming to expand our sales and to strengthen our business foundations in the growing ASEAN market Establishment of sales subsidiary in Malaysia and Vietnam Representative Office
March 12		Topline Results of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Anemia due to CKD
February 28		Tianjin Tanabe and Servier Tianjin join hands to promote TENELIA in China
February 20		Mitsubishi Tanabe Pharma Received Notice of Request for Arbitration
February 14		FDA accepted an Investigational New Drug Application for MT-8633, an ADC Targeting cMet Positive Solid Tumors
February 12		First Initiative in Digital Medicine Notice Regarding the Start of a Demonstration Project for TOMOCO, a Diabetes Care App
February 7		IR Meeting for FY2018 3rd Quarter Business Results[Transcript]
February 6		Swissmedic approves RADICAVA, Japan-originated ALS treatment
February 4		IR Meeting for FY2018 3rd Quarter Business Results[Material][Audio]
February 4		Announcement of FY2018 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
February 4		Notice Regarding Conclusion of Stock Transfer Agreement for Tanabe Seiyaku Yoshiki Factory Co., Ltd.

※ THE INCLUSION OF Mitsubishi Tanabe Pharma Corporation IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF Mitsubishi Tanabe Pharma Corporation BY MSCI OR ANY OF ITS AFFILIATES.
THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES.